Personalis, Inc. provided earnings guidance for the full year of 2022. For the year, the company's total company revenue is expected to be in the range of $62.0 million to $67.0 million; Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be in the range of $55.0 million to $60.0 million; and Net loss is expected to be in the range of $110.0 million to $115.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.3 USD | -0.76% | -2.99% | -38.10% |
08/05 | Transcript : Personalis, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
08/05 | Earnings Flash (PSNL) PERSONALIS Reports Q1 Revenue $19.5M, vs. Street Est of $18.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.10% | 6.8Cr | |
+43.36% | 5.81TCr | |
-5.31% | 4.05TCr | |
+37.52% | 3.9TCr | |
+14.75% | 2.67TCr | |
-12.56% | 2.66TCr | |
-22.45% | 1.9TCr | |
+0.04% | 1.22TCr | |
+25.12% | 1.2TCr | |
+26.04% | 1.19TCr |
- Stock Market
- Equities
- PSNL Stock
- News Personalis, Inc.
- Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022